The US FDA had conducted an inspection at the company’s aforementioned unit from 9 June to 13 June 2025.
Post the inspection, the company received one observation in Form-483, which was classified as ‘voluntary action indicated (VAI)’.
In a regulatory filing made during market hours today, Natco Pharma announced that it has received an establishment inspection report (EIR) for its API facility located in Mekaguda.
NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.
The company’s consolidated net profit increased 5.3% to Rs 406.60 crore on a 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24.
Shares of Natco Pharma slipped 3% to Rs 1,003.75 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."